Page 268 - Read Online

Page 10 of 11 Mizejewski. J Cancer Metastasis Treat 2019;5:35 I http://dx.doi.org/10.20517/2394-4722.2018.70

Mol Cancer 2017;16:176.
5. Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell 2016;166:21-45.
6. Mukherjee D, Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013;3:46-57.
7. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
8. Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large
oncosomes. Semin Cell Dev Biol 2015;40:41-51.
9. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts.
Semin Cancer Biol 2011;21:139-46.
10. Cavallaro S. CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci 2013;14:1713-27.
11. Mizejewski GJ. Breast cancer, chemokines, and metastases: a search for decoy ligands of the CXCR4 receptor. J Neoplasms 2018;1:1-9.
12. Tran-Thanh D, Done SJ. The role of stromal factors in breast tumorigenicity. Am J Pathol 2010;176:1072-4.
13. Scala S. Molecular Pathways: Targeting the CXCR4-CXCL12 axis--untapped potential in the tumor microenvironment. Clin Cancer Res
2015;21:4278-85.
14. Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. J Cell Sci 2001;114:629-41.
15. Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol 2009;41:349-69.
16. Mizejewski GJ. The third domain ligand binding fragment of alpha-fetoprotein: detection of metastasis-associated molecular targets.
Canc Therapy & Oncol Intl J 2017;6:1-15.
17 Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular
cell biology. Arterioscler Thromb Vasc Biol 2003;23:953-64.
18. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
19. Zhu P, Sun Y, Xu R, Sang Y, Zhao J, et al. The interaction between ADAM 22 and 14-3-3zeta: regulation of cell adhesion and spreading.
Biochem Biophys Res Commun 2003;301:991-999.
20. Collier IE, Bruns GA, Goldberg GI, Gerhard DS. On the structure and chromosome location of the 72- and 92-kDa human type IV
collagenase genes. Genomics 1991;9:429-34.
21. White DJ, Puranen S, Johnson MS, Heino J. The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 2004;36:1405-10.
22. Hauptmann R, Maurer-Fogy I, Krystek E, Bodo G, Andree H, et al. Vascular anticoagulant beta: a novel human Ca2+/phospholipid
binding protein that inhibits coagulation and phospholipase A2 activity. Its molecular cloning, expression and comparison with VAC-
alpha. Eur J Biochem 1989;185:63-71.
23. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem
1996;271:15292-7.
24 Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-
coupled receptor. Nature 2001;411:613-7.
25. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, et al. Characterization of two high affinity human interleukin-8 receptors. J Biol
Chem 1992;267:16283-7.
26. Yamda Y, Post SR, Wang K, Tager HS, Bell GI, et al. Cloning and functional characteristic of a family of human somatostatin receptors
expressed in brain, gastrointestinal tract and kidney. J N Acad Sci (USA) 1992;89:251-5.
27. Ron D, Reich R, Chedid M, Lengel C, Cohen OE, et al. Fibroblast growth factor receptor 4 is a high affinity receptor for both acidic and
basic fibroblast growth factor but not for keratinocyte growth factor. J Biol Chem 1993;268:5388-94.
28. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and
functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997;94:7192-7.
29. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. Nature
1986;320:84-5.
30. Critton DA, Tortajada A, Stetson G, Peti W, Page R. Structural basis of substrate recognition by hematopoietic tyrosine phosphatase.
Biochemistry 2008;47:13336-45.
31. Muehlemann M, Miller KD, Dauphinee M, Mizejewski GJ. Review of growth inhibitory peptide as a biotherapeutic agent for tumor
growth, adhesion, and metastasis. Cancer Metastasis Rev 2005;24:441-467.
32. Mizejewski GJ. Cancer, circulating tumor cells, and metastasis: could protein-derived peptide fragments impede brain metastasis? J
Cancer Metastasis Treat 2018;4:27.
33. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-99.
34. Cao Y, Ji RW, Davidson D, Schaller J, Marti D, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative
activity on endothelial cells. J Biol Chem 1996;271:29461-7.
35. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res 2006;312:594-607.
36. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, et al. Endothelin. Pharmacol Rev 2016;68:357-418.
37. Mizejewski GJ, MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics Mol Cancer Ther
2003;2:1243-55.
38. Mizejewski GJ, Butterstein G. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and
prospects. Curr Protein Pept Sci 2006;7:73-100.
39. Mizejewski GJ, Muehlemann M, Dauphinee M. Update of alpha fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor
growth and metastasis. Chemotherapy 2006;52:83-90.
40. Mizejewski GJ. The alpha-fetoprotein-derived growth inhibitory peptide 8-mer fragment: review of a novel anticancer agent. Cancer
Biother Radiopharm 2007;22:73-98.
41. Mizejewski GJ. The alpha-fetoprotein (AFP) third domain: a search for AFP interaction sites of cell cycle proteins. Tumour Biol
2016;37:12697-711.